Ichnos Glenmark Innovation, a clinical stage biotechnology company focused on oncology, has announced promising results for an innovative drug used for the treatment of relapsed or refractory multiple myeloma (RRMM), a rare form of blood cancer that affects plasma cells in bone marrow.

临床阶段生物技术公司Ichnos Glenmark Innovation专注于肿瘤学领域，近日宣布了一种用于治疗复发或难治性多发性骨髓瘤（RRMM）的创新药物取得可喜成果。多发性骨髓瘤是一种罕见的血液癌症，影响骨髓中的浆细胞。

Coded ISB 2001, the drug demonstrated an overall response rate (ORR) of 79% in a Phase 1 global study based on finding from patients who were administered a recommended dose. Patients who had exhausted other advanced treatments, such as CAR-T cell therapy and bi-specific antibodies, also showed encouraging results when given the drug..

编码为ISB 2001的药物在一项基于推荐剂量患者的全球一期研究中显示出79%的总体缓解率（ORR）。那些已经用尽其他先进治疗方法（如CAR-T细胞疗法和双特异性抗体）的患者在使用该药物后也显示出令人鼓舞的结果。

IGI is an alliance between the New York-based scientific research group Ichnos Sciences and Indian drug maker Glenmark.

IGI是总部位于纽约的科学研究组织Ichnos Sciences与印度制药商Glenmark之间的联盟。

Senior haematologists say that the drug could potentially be an important candidate in the treatment of patients - who exhaust other therapy options due - to its unique mechanism of engaging the body’s T cells (that are a vital part of the immune system) along with the attacking two sites on the tumour cell..

资深血液病学家表示，这种药物由于其独特的机制，能够调动人体的T细胞（免疫系统的重要组成部分），同时攻击肿瘤细胞上的两个位点，因此可能成为治疗那些已无其他疗法可选的患者的重要候选药物。

Dr Shyam Rathi, consultant, clinical hematology, PD Hinduja Hospital & Medical Research Centre in Mumbai, said: “It can definitely be a game changer in treatment of multiple myeloma which keeps relapsing thus exhausting treatment options quickly. This new drug looks very attractive because it targets two different sites on the cancer cell and it engages the body’s own T-cells.” .

孟买PD Hinduja医院和医学研究中心的临床血液学顾问Shyam Rathi博士说：“这种新药可能会成为治疗多发性骨髓瘤的变革者，因为该病会不断复发，从而迅速耗尽治疗选择。这个新药非常有吸引力，因为它针对癌细胞上的两个不同位点，并且能够激活人体自身的T细胞。”

Live Events

现场活动

“We have existing bi-specific antibodies where the target is only one antigen and they develop resistance very fast. However, ISB 2001 targets the two sites on the cancer cell and we expect some better results. It looks exciting in the future.”

“我们现有的双特异性抗体仅针对一个抗原，它们很快就会产生耐药性。然而，ISB 2001靶向癌细胞上的两个位点，我们预计会有更好的效果。未来看起来令人兴奋。”

In lay terms, ISB 2001 binds to three sites on the cancer tumour. First, the ISB 2001 activates the CD-3 T-lymphocytes, which are the cells that have the natural attacking power against tumour cells. Next, it binds to two additional sites. The first is BCMA (a protein found on myeloma cells), which is the target for bi-specific antibodies but there is also CD38, which is the binding site of the widely prescribed drug called daratumumab, branded as Darzalex by Johnson & Johnson.

用通俗的话来说，ISB 2001会与癌症肿瘤上的三个位点结合。首先，ISB 2001激活CD-3 T淋巴细胞，这些细胞具有对肿瘤细胞的天然攻击能力。接着，它会与另外两个位点结合。第一个是BCMA（一种在骨髓瘤细胞上发现的蛋白质），这是双特异性抗体的目标；另一个是CD38，这是广泛使用的药物达拉图单抗（Darzalex，由强生公司生产）的结合位点。

.

。

Glenmark, which is pinning a lot of hopes on the new drug, is in advanced talks with multiple global Big Pharma companies for a licensing deal, Chairman and Managing Director Glenn Saldanha told analysts over an earnings call recently. “The discussions are progressing really well, and we anticipate a positive outcome very quickly,” said Saldhana.

Glenmark 公司董事长兼总经理格伦·萨尔丹哈最近在一次业绩电话会议上告诉分析师，公司对这种新药寄予厚望，正在与多家全球大型制药公司进行深入谈判以达成许可协议。萨尔丹哈表示：“谈判进展非常顺利，我们预计很快就会有积极的结果。”

He said a deal for ISB 2001 will “really be transformational for Glenmark” and “will overshadow anything else that we are doing in the near term.” “You should see some visibility around a licensing deal pretty quickly.”.

他说，ISB 2001 的交易将“对 Glenmark 来说真的是变革性的”，并“将在短期内掩盖我们正在做的其他任何事情。” “你应该很快就能看到有关许可协议的一些进展。”

Last year Ichnos and Glenmark entered into a partnership for discovery of cutting-edge therapies, specifically to treat blood related cancers and malignancies like multiple myeloma. The global market for multiple myeloma treatment is seeing a surge. The business for such drugs is expected to rise to $33 billion by 2030, up from $23.5 billion in 2023,according to Bloomberg Intelligence estimates.

去年，Ichnos和Glenmark达成合作伙伴关系，共同发现前沿疗法，特别是用于治疗血液相关癌症和恶性肿瘤，如多发性骨髓瘤。全球多发性骨髓瘤治疗市场正在激增。根据彭博资讯的估计，此类药物的市场规模预计将从2023年的235亿美元增长到2030年的330亿美元。

.

。

Hang Quach, professor of haematology at the University of Melbourne noted that the data presented on ISB 2001 highlighted the “remarkable anti-myeloma activity of this first-in-class trispecific antibody-T cell engager in heavily pre-treated RRMM patients” including those who have exhausted other approved therapies.

墨尔本大学血液学教授杭·夸克指出，关于ISB 2001所展示的数据强调了“这种首创的三特异性抗体-T细胞接合器在经过多线治疗的复发/难治性多发性骨髓瘤（RRMM）患者中表现出显著的抗骨髓瘤活性”，其中包括那些已用尽其他获批疗法的患者。

.

。

According to Quach, ISB 2001 has the potential “to redefine the treatment landscape for multiple myeloma, offering new hope for patients with limited therapeutic options.”

根据Quach的说法，ISB 2001有潜力“重新定义多发性骨髓瘤的治疗前景，为治疗选择有限的患者提供新的希望。”

The drug demonstrated a favourable safety profile throughout the dose-escalation phase, with no dose-limiting toxicities (DLTs) reported.

该药物在剂量递增阶段表现出良好的安全性，未报告剂量限制性毒性（DLTs）。

(You can now subscribe to our

（你现在可以订阅我们的

Economic Times WhatsApp channel

经济时报 WhatsApp 频道

)

)

(You can now subscribe to our

（您现在可以订阅我们的

Economic Times WhatsApp channel

经济时报 WhatsApp 频道

)

)